Exact Mass: 563.2802202
Exact Mass Matches: 563.2802202
Found 492 metabolites which its exact mass value is equals to given mass value 563.2802202,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Taurolithocholate 3-sulfate
Taurolithocholic acid 3-sulfate is a sulfated bile acid. Under normal circumstances, bile acid sulfation is a minor pathway. However in the presence of cholestasis, the fraction of the bile acid pool which is sulfated increases. Sulfation of bile acids increases the aqueous solubility of the amphipathic compounds and results in more efficient renal clearance as well as in decreased reabsorption from the intestinal lumen. Bile acids are steroid acids found predominantly in the bile of mammals. The distinction between different bile acids is minute, depending only on the presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g. membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues (PMID: 11316487, 16037564, 12576301, 11907135). Taurolithocholic acid 3-sulfate is a sulfated bile acid. Under normal circumstances, bile acid sulfation is a minor pathway. However in the presence of cholestasis, the fraction of the bile acid pool which is sulfated increases. Sulfation of bile acids increases the aqueous solubility of the amphipathic compounds and results in more efficient renal clearance as well as in decreased reabsorption from the intestinal lumen. Bile acids are steroid acids found predominantly in bile of mammals. The distinction between different bile acids is minute, depends only on presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g., membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues. (PMID: 11316487, 16037564, 12576301, 11907135) [HMDB] D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids KEIO_ID T072
Fosinopril
Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3324
Alpha-Hydroxy-tamoxifen-O-glucuronide
Alpha-Hydroxy-tamoxifen-O-glucuronide is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)
4-Hydroxytamoxifen-O-glucuronide
4-Hydroxytamoxifen-O-glucuronide is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)
(E)-3-Hydroxy Tamoxifen O-|A-D-Glucuronide
Dihydroergocornine
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists
Elacridar
C1744 - Multidrug Resistance Modulator
Fosenopril
Phe Ile Arg Glu
Phe Glu Ile Arg
Asn Arg Phe Lys
C25H41N9O6 (563.3179646000001)
fosinopril
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents CONFIDENCE standard compound; INTERNAL_ID 2247
Tamoxifen citrate
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D050071 - Bone Density Conservation Agents D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent
3alpha-Sulfatolithocholyltaurine
BA-149-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-149-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-149-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-149-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-149-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
Cys Lys Lys Trp
C26H41N7O5S (563.2889736000001)
Cys Lys Gln Trp
Cys Lys Trp Lys
C26H41N7O5S (563.2889736000001)
Cys Lys Trp Gln
Cys Gln Lys Trp
Cys Gln Trp Lys
Cys Trp Lys Lys
C26H41N7O5S (563.2889736000001)
Cys Trp Lys Gln
Cys Trp Gln Lys
Asp Phe Pro Trp
Asp Phe Trp Pro
Asp His His Arg
C22H33N11O7 (563.2564308000001)
Asp His Arg His
C22H33N11O7 (563.2564308000001)
Asp Ile Met Trp
Asp Ile Trp Met
Asp Leu Met Trp
Asp Leu Trp Met
Asp Met Ile Trp
Asp Met Leu Trp
Asp Met Trp Ile
Asp Met Trp Leu
Asp Pro Phe Trp
Asp Pro Trp Phe
Asp Arg His His
C22H33N11O7 (563.2564308000001)
Asp Trp Phe Pro
Asp Trp Ile Met
Asp Trp Leu Met
Asp Trp Met Ile
Asp Trp Met Leu
Asp Trp Pro Phe
Glu Glu Met Arg
C21H37N7O9S (563.2373352000001)
Glu Glu Arg Met
C21H37N7O9S (563.2373352000001)
Glu Phe Ile Arg
Glu Phe Leu Arg
Glu Phe Arg Ile
Glu Phe Arg Leu
Glu Ile Phe Arg
Glu Ile Arg Phe
Glu Leu Phe Arg
Glu Leu Arg Phe
Glu Met Glu Arg
C21H37N7O9S (563.2373352000001)
Glu Met Arg Glu
C21H37N7O9S (563.2373352000001)
Glu Met Val Trp
Glu Met Trp Val
Glu Pro Arg Tyr
C25H37N7O8 (563.2703482000001)
Glu Pro Tyr Arg
C25H37N7O8 (563.2703482000001)
Glu Arg Glu Met
C21H37N7O9S (563.2373352000001)
Glu Arg Phe Ile
Glu Arg Phe Leu
Glu Arg Ile Phe
Glu Arg Leu Phe
Glu Arg Met Glu
C21H37N7O9S (563.2373352000001)
Glu Arg Pro Tyr
C25H37N7O8 (563.2703482000001)
Glu Arg Tyr Pro
C25H37N7O8 (563.2703482000001)
Glu Val Met Trp
Glu Val Trp Met
Glu Trp Met Val
Glu Trp Val Met
Glu Tyr Pro Arg
C25H37N7O8 (563.2703482000001)
Glu Tyr Arg Pro
C25H37N7O8 (563.2703482000001)
Phe Asp Pro Trp
Phe Asp Trp Pro
Phe Glu Leu Arg
Phe Glu Arg Ile
Phe Glu Arg Leu
Phe Phe His Asn
Phe Phe Asn His
Phe His Phe Asn
Phe His Asn Phe
Phe Ile Glu Arg
Phe Ile Val Trp
Phe Ile Trp Val
Phe Lys Asn Arg
C25H41N9O6 (563.3179646000001)
Phe Lys Arg Asn
C25H41N9O6 (563.3179646000001)
Phe Leu Glu Arg
Phe Leu Arg Glu
Phe Leu Val Trp
Phe Leu Trp Val
Phe Asn Phe His
Phe Asn His Phe
Phe Asn Lys Arg
C25H41N9O6 (563.3179646000001)
Phe Asn Gln Arg
Phe Asn Arg Lys
C25H41N9O6 (563.3179646000001)
Phe Asn Arg Gln
Phe Pro Asp Trp
Phe Pro Trp Asp
Phe Gln Asn Arg
Phe Gln Arg Asn
Phe Arg Glu Ile
Phe Arg Glu Leu
Phe Arg Ile Glu
Phe Arg Lys Asn
C25H41N9O6 (563.3179646000001)
Phe Arg Leu Glu
Phe Arg Asn Lys
C25H41N9O6 (563.3179646000001)
Phe Arg Asn Gln
Phe Arg Gln Asn
Phe Val Ile Trp
Phe Val Leu Trp
Phe Val Trp Ile
Phe Val Trp Leu
Phe Trp Asp Pro
Phe Trp Ile Val
Phe Trp Leu Val
Phe Trp Pro Asp
Phe Trp Val Ile
Phe Trp Val Leu
His Asp His Arg
C22H33N11O7 (563.2564308000001)
His Asp Arg His
C22H33N11O7 (563.2564308000001)
His Phe Phe Asn
His Phe Asn Phe
His His Asp Arg
C22H33N11O7 (563.2564308000001)
His His Arg Asp
C22H33N11O7 (563.2564308000001)
His Asn Phe Phe
His Arg Asp His
C22H33N11O7 (563.2564308000001)
His Arg His Asp
C22H33N11O7 (563.2564308000001)
Ile Asp Met Trp
Ile Asp Trp Met
Ile Glu Phe Arg
Ile Glu Arg Phe
Ile Phe Glu Arg
Ile Phe Arg Glu
Ile Phe Val Trp
Ile Phe Trp Val
Ile Met Asp Trp
Ile Met Trp Asp
Ile Arg Glu Phe
Ile Arg Phe Glu
Ile Val Phe Trp
Ile Val Trp Phe
Ile Trp Asp Met
Ile Trp Phe Val
Ile Trp Met Asp
Ile Trp Val Phe
Lys Cys Lys Trp
C26H41N7O5S (563.2889736000001)
Lys Cys Gln Trp
Lys Cys Trp Lys
C26H41N7O5S (563.2889736000001)
Lys Cys Trp Gln
Lys Phe Asn Arg
C25H41N9O6 (563.3179646000001)
Lys Phe Arg Asn
C25H41N9O6 (563.3179646000001)
Lys Lys Cys Trp
C26H41N7O5S (563.2889736000001)
Lys Lys Trp Cys
C26H41N7O5S (563.2889736000001)
Lys Asn Phe Arg
C25H41N9O6 (563.3179646000001)
Lys Asn Arg Phe
C25H41N9O6 (563.3179646000001)
Lys Gln Cys Trp
Lys Gln Trp Cys
Lys Arg Phe Asn
C25H41N9O6 (563.3179646000001)
Lys Arg Asn Phe
C25H41N9O6 (563.3179646000001)
Lys Trp Cys Lys
C26H41N7O5S (563.2889736000001)
Lys Trp Cys Gln
Lys Trp Lys Cys
C26H41N7O5S (563.2889736000001)
Lys Trp Gln Cys
Leu Asp Met Trp
Leu Asp Trp Met
Leu Glu Phe Arg
Leu Glu Arg Phe
Leu Phe Glu Arg
Leu Phe Arg Glu
Leu Phe Val Trp
Leu Phe Trp Val
Leu Met Asp Trp
Leu Met Trp Asp
Leu Arg Glu Phe
Leu Arg Phe Glu
Leu Val Phe Trp
Leu Val Trp Phe
Leu Trp Asp Met
Leu Trp Phe Val
Leu Trp Met Asp
Leu Trp Val Phe
Met Asp Ile Trp
Met Asp Leu Trp
Met Asp Trp Ile
Met Asp Trp Leu
Met Glu Glu Arg
C21H37N7O9S (563.2373352000001)
Met Glu Arg Glu
C21H37N7O9S (563.2373352000001)
Met Glu Val Trp
Met Glu Trp Val
Met Ile Asp Trp
Met Ile Trp Asp
Met Leu Asp Trp
Met Leu Trp Asp
Met Arg Glu Glu
C21H37N7O9S (563.2373352000001)
Met Val Glu Trp
Met Val Trp Glu
Met Trp Asp Ile
Met Trp Asp Leu
Met Trp Glu Val
Met Trp Ile Asp
Met Trp Leu Asp
Met Trp Val Glu
Asn Phe Phe His
Asn Phe His Phe
Asn Phe Lys Arg
C25H41N9O6 (563.3179646000001)
Asn Phe Gln Arg
Asn Phe Arg Lys
C25H41N9O6 (563.3179646000001)
Asn Phe Arg Gln
Asn His Phe Phe
Asn Lys Phe Arg
C25H41N9O6 (563.3179646000001)
Asn Lys Arg Phe
C25H41N9O6 (563.3179646000001)
Asn Gln Phe Arg
Asn Gln Arg Phe
Asn Arg Phe Gln
Asn Arg Lys Phe
C25H41N9O6 (563.3179646000001)
Asn Arg Gln Phe
Pro Asp Phe Trp
Pro Asp Trp Phe
Pro Glu Arg Tyr
C25H37N7O8 (563.2703482000001)
Pro Glu Tyr Arg
C25H37N7O8 (563.2703482000001)
Pro Phe Asp Trp
Pro Phe Trp Asp
Pro Arg Glu Tyr
C25H37N7O8 (563.2703482000001)
Pro Arg Tyr Glu
C25H37N7O8 (563.2703482000001)
Pro Val Trp Tyr
Pro Val Tyr Trp
Pro Trp Asp Phe
Pro Trp Phe Asp
Pro Trp Val Tyr
Pro Trp Tyr Val
Pro Tyr Glu Arg
C25H37N7O8 (563.2703482000001)
Pro Tyr Arg Glu
C25H37N7O8 (563.2703482000001)
Pro Tyr Val Trp
Pro Tyr Trp Val
Gln Cys Lys Trp
Gln Cys Trp Lys
Gln Phe Asn Arg
Gln Phe Arg Asn
Gln Lys Cys Trp
Gln Lys Trp Cys
Gln Asn Phe Arg
Gln Asn Arg Phe
Gln Arg Phe Asn
Gln Arg Asn Phe
Gln Trp Cys Lys
Gln Trp Lys Cys
Arg Asp His His
C22H33N11O7 (563.2564308000001)
Arg Glu Glu Met
C21H37N7O9S (563.2373352000001)
Arg Glu Phe Ile
Arg Glu Phe Leu
Arg Glu Ile Phe
Arg Glu Leu Phe
Arg Glu Met Glu
C21H37N7O9S (563.2373352000001)
Arg Glu Pro Tyr
C25H37N7O8 (563.2703482000001)
Arg Glu Tyr Pro
C25H37N7O8 (563.2703482000001)
Arg Phe Glu Ile
Arg Phe Glu Leu
Arg Phe Ile Glu
Arg Phe Lys Asn
C25H41N9O6 (563.3179646000001)
Arg Phe Leu Glu
Arg Phe Asn Lys
C25H41N9O6 (563.3179646000001)
Arg Phe Asn Gln
Arg Phe Gln Asn
Arg His Asp His
C22H33N11O7 (563.2564308000001)
Arg His His Asp
C22H33N11O7 (563.2564308000001)
Arg Ile Glu Phe
Arg Ile Phe Glu
Arg Lys Phe Asn
C25H41N9O6 (563.3179646000001)
Arg Lys Asn Phe
C25H41N9O6 (563.3179646000001)
Arg Leu Glu Phe
Arg Leu Phe Glu
Arg Met Glu Glu
C21H37N7O9S (563.2373352000001)
Arg Asn Phe Lys
C25H41N9O6 (563.3179646000001)
Arg Asn Phe Gln
Arg Asn Lys Phe
C25H41N9O6 (563.3179646000001)
Arg Asn Gln Phe
Arg Pro Glu Tyr
C25H37N7O8 (563.2703482000001)
Arg Pro Tyr Glu
C25H37N7O8 (563.2703482000001)
Arg Gln Phe Asn
Arg Gln Asn Phe
Arg Tyr Glu Pro
C25H37N7O8 (563.2703482000001)
Arg Tyr Pro Glu
C25H37N7O8 (563.2703482000001)
Val Glu Met Trp
Val Glu Trp Met
Val Phe Ile Trp
Val Phe Leu Trp
Val Phe Trp Ile
Val Phe Trp Leu
Val Ile Phe Trp
Val Ile Trp Phe
Val Leu Phe Trp
Val Leu Trp Phe
Val Met Glu Trp
Val Met Trp Glu
Val Pro Trp Tyr
Val Pro Tyr Trp
Val Trp Glu Met
Val Trp Phe Ile
Val Trp Phe Leu
Val Trp Ile Phe
Val Trp Leu Phe
Val Trp Met Glu
Val Trp Pro Tyr
Val Trp Tyr Pro
Val Tyr Pro Trp
Val Tyr Trp Pro
Trp Cys Lys Lys
C26H41N7O5S (563.2889736000001)
Trp Cys Lys Gln
Trp Cys Gln Lys
Trp Asp Phe Pro
Trp Asp Ile Met
Trp Asp Leu Met
Trp Asp Met Ile
Trp Asp Met Leu
Trp Asp Pro Phe
Trp Glu Met Val
Trp Glu Val Met
Trp Phe Asp Pro
Trp Phe Ile Val
Trp Phe Leu Val
Trp Phe Pro Asp
Trp Phe Val Ile
Trp Phe Val Leu
Trp Ile Asp Met
Trp Ile Phe Val
Trp Ile Met Asp
Trp Ile Val Phe
Trp Lys Cys Lys
C26H41N7O5S (563.2889736000001)
Trp Lys Cys Gln
Trp Lys Lys Cys
C26H41N7O5S (563.2889736000001)
Trp Lys Gln Cys
Trp Leu Asp Met
Trp Leu Phe Val
Trp Leu Met Asp
Trp Leu Val Phe
Trp Met Asp Ile
Trp Met Asp Leu
Trp Met Glu Val
Trp Met Ile Asp
Trp Met Leu Asp
Trp Met Val Glu
Trp Pro Asp Phe
Trp Pro Phe Asp
Trp Pro Val Tyr
Trp Pro Tyr Val
Trp Gln Cys Lys
Trp Gln Lys Cys
Trp Val Glu Met
Trp Val Phe Ile
Trp Val Phe Leu
Trp Val Ile Phe
Trp Val Leu Phe
Trp Val Met Glu
Trp Val Pro Tyr
Trp Val Tyr Pro
Trp Tyr Pro Val
Trp Tyr Val Pro
Tyr Glu Pro Arg
C25H37N7O8 (563.2703482000001)
Tyr Glu Arg Pro
C25H37N7O8 (563.2703482000001)
Tyr Pro Glu Arg
C25H37N7O8 (563.2703482000001)
Tyr Pro Arg Glu
C25H37N7O8 (563.2703482000001)
Tyr Pro Val Trp
Tyr Pro Trp Val
Tyr Arg Glu Pro
C25H37N7O8 (563.2703482000001)
Tyr Arg Pro Glu
C25H37N7O8 (563.2703482000001)
Tyr Val Pro Trp
Tyr Val Trp Pro
Tyr Trp Pro Val
Tyr Trp Val Pro
Dihydroergocornine
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists Ergocornine in which a single bond replaces the double bond between positions 9 and 10. C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist
3-[[4-[[diamino(phenylazo)phenyl]azo]-1-naphthyl]azo]-N,N,N-trimethylanilinium chloride
disodium 4-[1-methyl-2-[(1-oxooctadec-9-enyl)amino]ethyl] 2-sulphonatosuccinate
Ethyl 4-{4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-oxobutyl}-alpha,alpha-dimethylbenzeneacetate hydrochloride
NNC 55-0396 dihydrochloride
D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
2-amino-N-[[(1R,2S,10R,12R,13S)-12-cyano-7,18-dimethoxy-6,17,21-trimethyl-5,8,16,19-tetraoxo-11,21-diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),6,15(20),17-tetraen-10-yl]methyl]propanamide
6-[3-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate
N-[(2S,3S)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
[(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(2-methoxyphenyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-morpholinyl)methanone
N-(2-aminophenyl)-4-[[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-[(4S,7R,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2,2,2-trifluoroethanesulfonamide
C26H40F3N3O5S (563.2640626000001)
N-[(4R,7R,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2,2,2-trifluoroethanesulfonamide
C26H40F3N3O5S (563.2640626000001)
N-[(4R,7S,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2,2,2-trifluoroethanesulfonamide
C26H40F3N3O5S (563.2640626000001)
N-[(4R,7R,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2,2,2-trifluoroethanesulfonamide
C26H40F3N3O5S (563.2640626000001)
N-[(2R,3S)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2S,3S)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2S,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide
N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-thiophenesulfonamide
C28H41N3O5S2 (563.2487496000001)
N-(2-aminophenyl)-4-[[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-thiophenesulfonamide
C28H41N3O5S2 (563.2487496000001)
N-(2-aminophenyl)-4-[[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-(2-aminophenyl)-4-[[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-(2-aminophenyl)-4-[[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-(2-aminophenyl)-4-[[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-[(4S,7R,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2,2,2-trifluoroethanesulfonamide
C26H40F3N3O5S (563.2640626000001)
N-[(4R,7S,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2,2,2-trifluoroethanesulfonamide
C26H40F3N3O5S (563.2640626000001)
(1S)-N1-cyclopentyl-N2-(4-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-9-methylspiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]-1,2-dicarboxamide
N-[(2R,3R)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2S,3R)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2S,3R)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2R,3S)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2R,3R)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2S,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide
N-[(2S,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide
N-(2-aminophenyl)-4-[[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-thiophenesulfonamide
C28H41N3O5S2 (563.2487496000001)
N-(2-aminophenyl)-4-[[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-(2-aminophenyl)-4-[[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-(2-aminophenyl)-4-[[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-(2-aminophenyl)-4-[[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-(2-aminophenyl)-4-[[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-(2-aminophenyl)-4-[[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-(2-aminophenyl)-4-[[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-(2-aminophenyl)-4-[[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl-methylamino]methyl]benzamide
C30H41N7O4 (563.3219866000001)
N-[(4S,7S,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2,2,2-trifluoroethanesulfonamide
C26H40F3N3O5S (563.2640626000001)
N-[(4S,7S,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2,2,2-trifluoroethanesulfonamide
C26H40F3N3O5S (563.2640626000001)
[(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-4-[3-(2-methoxyphenyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-(4-morpholinyl)methanone
(1R)-N1-cyclopentyl-N2-(4-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-9-methylspiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]-1,2-dicarboxamide
2-amino-3-[[3-[(11Z,14Z)-henicosa-11,14-dienoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[[3-butanoyloxy-2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
(Z)-1-[2-Methyl-2,2-diphenyl-1-(2-methylphenyl)disilanyl]-2-phenyl-1,2-bis(trimethylsilyl)ethene
(2-Benzamido-3-phenylpropyl) 2-[(2-benzamido-3-phenylpropanoyl)amino]acetate
3-[[3-acetyloxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxy-2-aminopropanoic acid
Taurolithocholic acid 3-sulfate
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
Taurolithocholic acid sulfate
The steroid sulfate of taurolithocholic acid.
Fesoterodine (L-mandelate)
Fesoterodine L-mandelate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine L-mandelate is used for the overactive bladder (OAB)[1][2].
(4s)-n-{2-hydroxy-4,7-diisopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl}-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(15),2,12(16),13-tetraene-4-carboximidic acid
(1s,2s,4s,5r,10r,11s,14r,15r,18s)-5-hydroxy-10,14-dimethyl-15-[(1s)-1-[(3r,5r)-5,6,6-trimethyl-1-(pyridin-3-yl)-2,7,8-trioxabicyclo[3.2.1]octan-3-yl]ethyl]-3-oxapentacyclo[9.7.0.0²,⁴.0⁵,¹⁰.0¹⁴,¹⁸]octadec-7-en-9-one
2,19-dihydroxy-6,12,22-trioxo-21-(sec-butyl)-23-oxa-3,7,13,20,27-pentaazatetracyclo[22.3.1.0⁷,¹¹.0¹³,¹⁸]octacosa-2,19-diene-4-carboxylic acid
C27H41N5O8 (563.2954986000001)